Our results reveal that tyrosine kinase SYK activation plays a pivotal role in sustaining proliferation and survival of aggressive pediatric ETV6-RUNX1 B-ALL cells, and it can be targeted in order to reverse drug resistance. Here, RUNX1 is linked to acute lymphoblastic leukemia.